Pfizer Inc. (PFE), along with four of its units and a local Indonesian company, did not breach anti-monopoly laws, according to an Indonesian court, reversing a ruling last year by the country's antitrust agency. The antitrust agency--locally known as KPPU--found Pfizer, subsidiaries and local company Dexa Medica had wrongly used a dominant position in the anti- hypertensive-products market to overcharge consumers. The subsidiaries involved were PT Pfizer Indonesia (PD-PFE), Pfizer Overseas LLC, Pfizer Global Trading and Pfizer Corporation Panama.